Fulgent Genetics, Inc.

How big is Fulgent Genetics, Inc.?

As of Jun 18, Fulgent Genetics, Inc. has a market capitalization of 616.79 million and reported net sales of 292.44 million with a net profit of -41.87 million over the latest four quarters. Shareholder's funds are 1,133.23 million, and total assets amount to 1,257.08 million.

As of Jun 18, Fulgent Genetics, Inc. has a market capitalization of 616.79 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 292.44 million, while the sum of net profit for the same period is -41.87 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 1,133.23 million, and the total assets amount to 1,257.08 million.

What does Fulgent Genetics, Inc. do?

Fulgent Genetics, Inc. is a biotechnology company that provides genetic testing for clinically actionable diagnostic information to enhance patient care. As of March 2025, it reported net sales of $73 million and a net loss of $12 million, with a market cap of $616.79 million.

Overview: <BR>Fulgent Genetics, Inc. is a technology company in the Pharmaceuticals & Biotechnology industry that offers genetic testing to provide physicians with clinically actionable diagnostic information to improve patient care.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 73 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -12 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 616.79 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.28 <BR>Return on Equity: -2.82% <BR>Price to Book: 0.55 <BR><BR>Contact Details: <BR>Address: 4978 Santa Anita Ave Ste 205, TEMPLE CITY CA: 91780-3600 <BR>Tel: ['1 626 3500537', '1 415 2175865'] <BR>Fax: 1 626 4541667 <BR>Website: https://www.fulgentgenetics.com/

Should I buy, sell or hold Fulgent Genetics, Inc.?

Who are in the management team of Fulgent Genetics, Inc.?

As of March 2022, the management team of Fulgent Genetics, Inc. includes Mr. Ming Hsieh as Chairman, President, and CEO, along with independent directors Mr. John Bolger, Ms. Linda Marsh, and Dr. Yun Yen.

As of March 2022, the management team of Fulgent Genetics, Inc. includes Mr. Ming Hsieh, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features independent directors: Mr. John Bolger, Ms. Linda Marsh, and Dr. Yun Yen.

Is Fulgent Genetics, Inc. overvalued or undervalued?

As of May 5, 2023, Fulgent Genetics, Inc. is considered risky and overvalued due to negative earnings metrics and low valuation ratios, with significantly worse financial metrics compared to peers like Ginkgo Bioworks, indicating challenges in profitability and market performance.

As of 5 May 2023, the valuation grade for Fulgent Genetics, Inc. has moved from expensive to risky, indicating a shift in perception regarding its financial health and market position. The company appears to be overvalued, particularly given its negative earnings metrics and low valuation ratios. Key ratios include a Price to Book Value of 0.58, an EV to EBIT of -4.67, and an EV to EBITDA of -7.04, all of which suggest significant challenges in profitability and valuation relative to its assets and earnings.<BR><BR>In comparison to peers, Fulgent Genetics has a P/E ratio of -21.2754 and an EV to EBITDA of -8.0743, which are considerably worse than Ginkgo Bioworks Holdings, Inc., which has a P/E of -2.1642 and an EV to EBITDA of -0.7299. This stark contrast highlights the relative weakness of Fulgent's financial metrics within the industry. While specific return data is not available, the absence of positive returns reinforces the notion that the stock may not be performing well relative to broader market benchmarks like the S&P 500.

Is Fulgent Genetics, Inc. technically bullish or bearish?

As of October 31, 2025, Fulgent Genetics, Inc. shows a mildly bullish trend with positive momentum indicators, but has underperformed the S&P 500 over the past year and longer, reflecting mixed signals and historical weakness.

As of 31 October 2025, the technical trend for Fulgent Genetics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating a positive momentum but with some weakening. The Bollinger Bands are bullish on both weekly and monthly time frames, supporting the upward price movement. Daily moving averages are also bullish. However, the RSI shows no signal on both weekly and monthly charts, and Dow Theory indicates no trend in either time frame. <BR><BR>In terms of performance, Fulgent Genetics has underperformed the S&P 500 over the past year and three to five years, with returns of 5.88% and -39.61% respectively, compared to the S&P 500's 19.89% and 76.66%. Overall, the current stance is mildly bullish, but the strength is tempered by mixed signals and historical underperformance.